APO Research
Talk to an analyst

APO RESEARCH · REPORT

Overactive Bladder (OAB) Therapeutics

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Overactive Bladder (OAB) Therapeutics Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

20 December 2025194 pages

Choose your research edition.

Industry ResearchOveractive Bladder (OAB) Therapeutics Industry Research Report 2026124 pages · $2,950 USDIndustry Growth & TrendsGlobal Overactive Bladder (OAB) Therapeutics Industry Growth and Trends Forecast to 2032104 pages · $3,450 USDMarket StructureGlobal Overactive Bladder (OAB) Therapeutics Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032194 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Overactive Bladder (OAB) Therapeutics Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Overactive Bladder (OAB) Therapeutics Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

The global Overactive Bladder (OAB) Therapeutics market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Overactive Bladder (OAB) Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Overactive Bladder (OAB) Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Overactive Bladder (OAB) Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Overactive Bladder (OAB) Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Overactive Bladder (OAB) Therapeutics include Allergan, Astellas Pharma, Hisamitsu Pharmaceutical, Ion Channel Innovations, Kwang Dong Pharmaceutical, ONO Pharmaceutical, Tengion, GlaxoSmithKline and Ferring, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Overactive Bladder (OAB) Therapeutics market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Overactive Bladder (OAB) Therapeutics and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Overactive Bladder (OAB) Therapeutics sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Overactive Bladder (OAB) Therapeutics market size, projected growth trends, production technologies, key applications, and end-use industries.

Overactive Bladder (OAB) Therapeutics Segment by Company

Allergan

Astellas Pharma

Hisamitsu Pharmaceutical

Ion Channel Innovations

Kwang Dong Pharmaceutical

ONO Pharmaceutical

Tengion

GlaxoSmithKline

Ferring

Pfizer

Lanzhou Institute of Biological Products

Merck

Sanofi

Teva Pharmaceutical Industries

Overactive Bladder (OAB) Therapeutics Segment by Type

Anticholinergic Agents

Beta-3 Adrenoreceptor Agonists

Overactive Bladder (OAB) Therapeutics Segment by Application

Hosptial

Clinci

Other

Overactive Bladder (OAB) Therapeutics Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Overactive Bladder (OAB) Therapeutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Overactive Bladder (OAB) Therapeutics and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Overactive Bladder (OAB) Therapeutics.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Overactive Bladder (OAB) Therapeutics market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Overactive Bladder (OAB) Therapeutics manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Overactive Bladder (OAB) Therapeutics in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Overactive Bladder (OAB) Therapeutics in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Overactive Bladder (OAB) Therapeutics Industry Trends Table 2. Overactive Bladder (OAB) Therapeutics Industry Drivers Table 3. Overactive Bladder (OAB) Therapeutics Industry Opportunities and Challenges Table 4. Overactive Bladder (OAB) Therapeutics Industry Restraints Table 5. Global Overactive Bladder (OAB) Therapeutics Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Overactive Bladder (OAB) Therapeutics Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Overactive Bladder (OAB) Therapeutics Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Overactive Bladder (OAB) Therapeutics Sales Market Share by Manufacturers Table 9. Global Overactive Bladder (OAB) Therapeutics Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Overactive Bladder (OAB) Therapeutics Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Overactive Bladder (OAB) Therapeutics Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Overactive Bladder (OAB) Therapeutics Manufacturers, Product Type & Application Table 13. Global Overactive Bladder (OAB) Therapeutics Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Overactive Bladder (OAB) Therapeutics by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Anticholinergic Agents Table 17. Major Manufacturers of Beta-3 Adrenoreceptor Agonists Table 18. Global Overactive Bladder (OAB) Therapeutics Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 19. Global Overactive Bladder (OAB) Therapeutics Sales by Type (2021-2026) & (K Units) Table 20. Global Overactive Bladder (OAB) Therapeutics Sales by Type (2027-2032) & (K Units) Table 21. Global Overactive Bladder (OAB) Therapeutics Sales Market Share by Type (2021-2026) Table 22. Global Overactive Bladder (OAB) Therapeutics Sales Market Share by Type (2027-2032) Table 23. Global Overactive Bladder (OAB) Therapeutics Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 24. Global Overactive Bladder (OAB) Therapeutics Revenue by Type (2021-2026) & (K Units) Table 25. Global Overactive Bladder (OAB) Therapeutics Revenue by Type (2027-2032) & (K Units) Table 26. Global Overactive Bladder (OAB) Therapeutics Revenue Market Share by Type (2021-2026) Table 27. Global Overactive Bladder (OAB) Therapeutics Revenue Market Share by Type (2027-2032) Table 28. Major Manufacturers of Hosptial Table 29. Major Manufacturers of Clinci Table 30. Major Manufacturers of Other Table 31. Global Overactive Bladder (OAB) Therapeutics Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 32. Global Overactive Bladder (OAB) Therapeutics Sales by Application (2021-2026) & (K Units) Table 33. Global Overactive Bladder (OAB) Therapeutics Sales by Application (2027-2032) & (K Units) Table 34. Global Overactive Bladder (OAB) Therapeutics Sales Market Share by Application (2021-2026) Table 35. Global Overactive Bladder (OAB) Therapeutics Sales Market Share by Application (2027-2032) Table 36. Global Overactive Bladder (OAB) Therapeutics Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 37. Global Overactive Bladder (OAB) Therapeutics Revenue by Application (2021-2026) & (K Units) Table 38. Global Overactive Bladder (OAB) Therapeutics Revenue by Application (2027-2032) & (K Units) Table 39. Global Overactive Bladder (OAB) Therapeutics Revenue Market Share by Application (2021-2026) Table 40. Global Overactive Bladder (OAB) Therapeutics Revenue Market Share by Application (2027-2032) Table 41. Global Overactive Bladder (OAB) Therapeutics Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 42. Global Overactive Bladder (OAB) Therapeutics Sales by Region (2021-2026) & (K Units) Table 43. Global Overactive Bladder (OAB) Therapeutics Sales Market Share by Region (2021-2026) Table 44. Global Overactive Bladder (OAB) Therapeutics Sales Forecasted by Region (2027-2032) & (K Units) Table 45. Global Overactive Bladder (OAB) Therapeutics Sales Forecasted Market Share by Region (2027-2032) Table 46. North America Overactive Bladder (OAB) Therapeutics Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 47. North America Overactive Bladder (OAB) Therapeutics Sales by Country (2021-2026) & (K Units) Table 48. North America Overactive Bladder (OAB) Therapeutics Sales by Country (2027-2032) & (K Units) Table 49. Europe Overactive Bladder (OAB) Therapeutics Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 50. Europe Overactive Bladder (OAB) Therapeutics Sales by Country (2021-2026) & (K Units) Table 51. Europe Overactive Bladder (OAB) Therapeutics Sales by Country (2027-2032) & (K Units) Table 52. Asia Pacific Overactive Bladder (OAB) Therapeutics Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 53. Asia Pacific Overactive Bladder (OAB) Therapeutics Sales by Country (2021-2026) & (K Units) Table 54. Asia Pacific Overactive Bladder (OAB) Therapeutics Sales by Country (2027-2032) & (K Units) Table 55. South America, Middle East and Africa Overactive Bladder (OAB) Therapeutics Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 56. South America, Middle East and Africa Overactive Bladder (OAB) Therapeutics Sales by Country (2021-2026) & (K Units) Table 57. South America, Middle East and Africa Overactive Bladder (OAB) Therapeutics Sales by Country (2027-2032) & (K Units) Table 58. Global Overactive Bladder (OAB) Therapeutics Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 59. Global Overactive Bladder (OAB) Therapeutics Revenue by Region (2021-2026) & (US$ Million) Table 60. Global Overactive Bladder (OAB) Therapeutics Revenue by Region (2027-2032) & (US$ Million) Table 61. Global Overactive Bladder (OAB) Therapeutics Revenue Market Share by Region (2021-2026) Table 62. Global Overactive Bladder (OAB) Therapeutics Revenue Market Share by Region (2027-2032) Table 63. Allergan Company Information Table 64. Allergan Business Overview Table 65. Allergan Overactive Bladder (OAB) Therapeutics Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 66. Allergan Overactive Bladder (OAB) Therapeutics Product Portfolio Table 67. Allergan Recent Development Table 68. Astellas Pharma Company Information Table 69. Astellas Pharma Business Overview Table 70. Astellas Pharma Overactive Bladder (OAB) Therapeutics Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. Astellas Pharma Overactive Bladder (OAB) Therapeutics Product Portfolio Table 72. Astellas Pharma Recent Development Table 73. Hisamitsu Pharmaceutical Company Information Table 74. Hisamitsu Pharmaceutical Business Overview Table 75. Hisamitsu Pharmaceutical Overactive Bladder (OAB) Therapeutics Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 76. Hisamitsu Pharmaceutical Overactive Bladder (OAB) Therapeutics Product Portfolio Table 77. Hisamitsu Pharmaceutical Recent Development Table 78. Ion Channel Innovations Company Information Table 79. Ion Channel Innovations Business Overview Table 80. Ion Channel Innovations Overactive Bladder (OAB) Therapeutics Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 81. Ion Channel Innovations Overactive Bladder (OAB) Therapeutics Product Portfolio Table 82. Ion Channel Innovations Recent Development Table 83. Kwang Dong Pharmaceutical Company Information Table 84. Kwang Dong Pharmaceutical Business Overview Table 85. Kwang Dong Pharmaceutical Overactive Bladder (OAB) Therapeutics Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 86. Kwang Dong Pharmaceutical Overactive Bladder (OAB) Therapeutics Product Portfolio Table 87. Kwang Dong Pharmaceutical Recent Development Table 88. ONO Pharmaceutical Company Information Table 89. ONO Pharmaceutical Business Overview Table 90. ONO Pharmaceutical Overactive Bladder (OAB) Therapeutics Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 91. ONO Pharmaceutical Overactive Bladder (OAB) Therapeutics Product Portfolio Table 92. ONO Pharmaceutical Recent Development Table 93. Tengion Company Information Table 94. Tengion Business Overview Table 95. Tengion Overactive Bladder (OAB) Therapeutics Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 96. Tengion Overactive Bladder (OAB) Therapeutics Product Portfolio Table 97. Tengion Recent Development Table 98. GlaxoSmithKline Company Information Table 99. GlaxoSmithKline Business Overview Table 100. GlaxoSmithKline Overactive Bladder (OAB) Therapeutics Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 101. GlaxoSmithKline Overactive Bladder (OAB) Therapeutics Product Portfolio Table 102. GlaxoSmithKline Recent Development Table 103. Ferring Company Information Table 104. Ferring Business Overview Table 105. Ferring Overactive Bladder (OAB) Therapeutics Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 106. Ferring Overactive Bladder (OAB) Therapeutics Product Portfolio Table 107. Ferring Recent Development Table 108. Pfizer Company Information Table 109. Pfizer Business Overview Table 110. Pfizer Overactive Bladder (OAB) Therapeutics Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 111. Pfizer Overactive Bladder (OAB) Therapeutics Product Portfolio Table 112. Pfizer Recent Development Table 113. Lanzhou Institute of Biological Products Company Information Table 114. Lanzhou Institute of Biological Products Business Overview Table 115. Lanzhou Institute of Biological Products Overactive Bladder (OAB) Therapeutics Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 116. Lanzhou Institute of Biological Products Overactive Bladder (OAB) Therapeutics Product Portfolio Table 117. Lanzhou Institute of Biological Products Recent Development Table 118. Merck Company Information Table 119. Merck Business Overview Table 120. Merck Overactive Bladder (OAB) Therapeutics Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 121. Merck Overactive Bladder (OAB) Therapeutics Product Portfolio Table 122. Merck Recent Development Table 123. Sanofi Company Information Table 124. Sanofi Business Overview Table 125. Sanofi Overactive Bladder (OAB) Therapeutics Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 126. Sanofi Overactive Bladder (OAB) Therapeutics Product Portfolio Table 127. Sanofi Recent Development Table 128. Teva Pharmaceutical Industries Company Information Table 129. Teva Pharmaceutical Industries Business Overview Table 130. Teva Pharmaceutical Industries Overactive Bladder (OAB) Therapeutics Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 131. Teva Pharmaceutical Industries Overactive Bladder (OAB) Therapeutics Product Portfolio Table 132. Teva Pharmaceutical Industries Recent Development Table 133. Key Raw Materials Table 134. Raw Materials Key Suppliers Table 135. Overactive Bladder (OAB) Therapeutics Distributors List Table 136. Overactive Bladder (OAB) Therapeutics Customers List Table 137. Research Programs/Design for This Report Table 138. Authors List of This Report Table 139. Secondary Sources Table 140. Primary Sources List of Figures Figure 1. Overactive Bladder (OAB) Therapeutics Product Image Figure 2. Global Overactive Bladder (OAB) Therapeutics Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Overactive Bladder (OAB) Therapeutics Market Size (2021-2032) & (US$ Million) Figure 4. Global Overactive Bladder (OAB) Therapeutics Sales (2021-2032) & (K Units) Figure 5. Global Overactive Bladder (OAB) Therapeutics Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Overactive Bladder (OAB) Therapeutics Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Anticholinergic Agents Image Figure 9. Beta-3 Adrenoreceptor Agonists Image Figure 10. Global Overactive Bladder (OAB) Therapeutics Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 11. Global Overactive Bladder (OAB) Therapeutics Sales Market Share 2021 VS 2025 VS 2032 Figure 12. Global Overactive Bladder (OAB) Therapeutics Sales Market Share by Type (2021-2032) Figure 13. Global Overactive Bladder (OAB) Therapeutics Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 14. Global Overactive Bladder (OAB) Therapeutics Revenue Market Share 2021 VS 2025 VS 2032 Figure 15. Global Overactive Bladder (OAB) Therapeutics Revenue Market Share by Type (2021-2032) Figure 16. Hosptial Image Figure 17. Clinci Image Figure 18. Other Image Figure 19. Global Overactive Bladder (OAB) Therapeutics Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 20. Global Overactive Bladder (OAB) Therapeutics Sales Market Share 2021 VS 2025 VS 2032 Figure 21. Global Overactive Bladder (OAB) Therapeutics Sales Market Share by Application (2021-2032) Figure 22. Global Overactive Bladder (OAB) Therapeutics Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 23. Global Overactive Bladder (OAB) Therapeutics Revenue Market Share 2021 VS 2025 VS 2032 Figure 24. Global Overactive Bladder (OAB) Therapeutics Revenue Market Share by Application (2021-2032) Figure 25. North America Overactive Bladder (OAB) Therapeutics Sales and Growth Rate (2021-2032) & (K Units) Figure 26. North America Overactive Bladder (OAB) Therapeutics Sales Market Share by Country (2021-2032) Figure 27. U.S. Overactive Bladder (OAB) Therapeutics Sales and Growth Rate (2021-2032) & (K Units) Figure 28. Canada Overactive Bladder (OAB) Therapeutics Sales and Growth Rate (2021-2032) & (K Units) Figure 29. Mexico Overactive Bladder (OAB) Therapeutics Sales and Growth Rate (2021-2032) & (K Units) Figure 30. Europe Overactive Bladder (OAB) Therapeutics Sales and Growth Rate (2021-2032) & (K Units) Figure 31. Europe Overactive Bladder (OAB) Therapeutics Sales Market Share by Country (2021-2032) Figure 32. Germany Overactive Bladder (OAB) Therapeutics Sales and Growth Rate (2021-2032) & (K Units) Figure 33. France Overactive Bladder (OAB) Therapeutics Sales and Growth Rate (2021-2032) & (K Units) Figure 34. U.K. Overactive Bladder (OAB) Therapeutics Sales and Growth Rate (2021-2032) & (K Units) Figure 35. Italy Overactive Bladder (OAB) Therapeutics Sales and Growth Rate (2021-2032) & (K Units) Figure 36. Netherlands Overactive Bladder (OAB) Therapeutics Sales and Growth Rate (2021-2032) & (K Units) Figure 37. Asia Pacific Overactive Bladder (OAB) Therapeutics Sales and Growth Rate (2021-2032) & (K Units) Figure 38. Asia Pacific Overactive Bladder (OAB) Therapeutics Sales Market Share by Country (2021-2032) Figure 39. China Overactive Bladder (OAB) Therapeutics Sales and Growth Rate (2021-2032) & (K Units) Figure 40. Japan Overactive Bladder (OAB) Therapeutics Sales and Growth Rate (2021-2032) & (K Units) Figure 41. South Korea Overactive Bladder (OAB) Therapeutics Sales and Growth Rate (2021-2032) & (K Units) Figure 42. Southeast Asia Overactive Bladder (OAB) Therapeutics Sales and Growth Rate (2021-2032) & (K Units) Figure 43. India Overactive Bladder (OAB) Therapeutics Sales and Growth Rate (2021-2032) & (K Units) Figure 44. Australia Overactive Bladder (OAB) Therapeutics Sales and Growth Rate (2021-2032) & (K Units) Figure 45. South America, Middle East and Africa Overactive Bladder (OAB) Therapeutics Sales and Growth Rate (2021-2032) & (K Units) Figure 46. South America, Middle East and Africa Overactive Bladder (OAB) Therapeutics Sales Market Share by Country (2021-2032) Figure 47. Brazil Overactive Bladder (OAB) Therapeutics Sales and Growth Rate (2021-2032) & (K Units) Figure 48. South Africa Overactive Bladder (OAB) Therapeutics Sales and Growth Rate (2021-2032) & (K Units) Figure 49. Saudi Arabia Overactive Bladder (OAB) Therapeutics Sales and Growth Rate (2021-2032) & (K Units) Figure 50. Turkey Overactive Bladder (OAB) Therapeutics Sales and Growth Rate (2021-2032) & (K Units) Figure 51. Argentina Overactive Bladder (OAB) Therapeutics Sales and Growth Rate (2021-2032) & (K Units) Figure 52. UAE Overactive Bladder (OAB) Therapeutics Sales and Growth Rate (2021-2032) & (K Units) Figure 53. Egypt Overactive Bladder (OAB) Therapeutics Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Chile Overactive Bladder (OAB) Therapeutics Sales and Growth Rate (2021-2032) & (K Units) Figure 55. Global Overactive Bladder (OAB) Therapeutics Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Global Overactive Bladder (OAB) Therapeutics Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 57. North America Overactive Bladder (OAB) Therapeutics Revenue (2021-2032) & (US$ Million) Figure 58. North America Overactive Bladder (OAB) Therapeutics Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 59. Europe Overactive Bladder (OAB) Therapeutics Revenue (2021-2032) & (US$ Million) Figure 60. Europe Overactive Bladder (OAB) Therapeutics Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 61. Asia-Pacific Overactive Bladder (OAB) Therapeutics Revenue (2021-2032) & (US$ Million) Figure 62. Asia-Pacific Overactive Bladder (OAB) Therapeutics Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. South America, Middle East and Africa Overactive Bladder (OAB) Therapeutics Revenue (2021-2032) & (US$ Million) Figure 64. South America, Middle East and Africa Overactive Bladder (OAB) Therapeutics Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. Overactive Bladder (OAB) Therapeutics Value Chain Figure 66. Manufacturing Cost Structure Figure 67. Overactive Bladder (OAB) Therapeutics Production Mode & Process Figure 68. Direct Comparison with Distribution Share Figure 69. Distributors Profiles Figure 70. Years Considered Figure 71. Research Process Figure 72. Key Executives Interviewed

Scope & coverage.

Types
  • Anticholinergic Agents
  • Beta-3 Adrenoreceptor Agonists
Applications
  • Hosptial
  • Clinci
  • Other
Companies covered
  • Allergan
  • Astellas Pharma
  • Hisamitsu Pharmaceutical
  • Ion Channel Innovations
  • Kwang Dong Pharmaceutical
  • ONO Pharmaceutical
  • Tengion
  • GlaxoSmithKline
  • Ferring
  • Pfizer
  • Lanzhou Institute of Biological Products
  • Merck
  • Sanofi
  • Teva Pharmaceutical Industries

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Overactive Bladder (OAB) Therapeutics Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Overactive Bladder (OAB) Therapeutics Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Overactive Bladder (OAB) Therapeutics Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Overactive Bladder (OAB) Therapeutics Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Overactive Bladder (OAB) Therapeutics Market Dynamics
  1. 2.1 Overactive Bladder (OAB) Therapeutics Industry Trends
  2. 2.2 Overactive Bladder (OAB) Therapeutics Industry Drivers
  3. 2.3 Overactive Bladder (OAB) Therapeutics Industry Opportunities and Challenges
  4. 2.4 Overactive Bladder (OAB) Therapeutics Industry Restraints
3 Overactive Bladder (OAB) Therapeutics Market by Manufacturers
  1. 3.1 Global Overactive Bladder (OAB) Therapeutics Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Overactive Bladder (OAB) Therapeutics Sales by Manufacturers (2021-2026)
  3. 3.3 Global Overactive Bladder (OAB) Therapeutics Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Overactive Bladder (OAB) Therapeutics Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Overactive Bladder (OAB) Therapeutics Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Overactive Bladder (OAB) Therapeutics Manufacturers, Product Type & Application
  7. 3.7 Global Overactive Bladder (OAB) Therapeutics Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Overactive Bladder (OAB) Therapeutics Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Overactive Bladder (OAB) Therapeutics Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Overactive Bladder (OAB) Therapeutics Tier 1, Tier 2, and Tier 3
4 Overactive Bladder (OAB) Therapeutics Market by Type
  1. 4.1 Overactive Bladder (OAB) Therapeutics Type Introduction
  2. 4.1.1 Anticholinergic Agents
  3. 4.1.2 Beta-3 Adrenoreceptor Agonists
  4. 4.2 Global Overactive Bladder (OAB) Therapeutics Sales by Type
  5. 4.2.1 Global Overactive Bladder (OAB) Therapeutics Sales by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Overactive Bladder (OAB) Therapeutics Sales by Type (2021-2032)
  7. 4.2.3 Global Overactive Bladder (OAB) Therapeutics Sales Market Share by Type (2021-2032)
  8. 4.3 Global Overactive Bladder (OAB) Therapeutics Revenue by Type
  9. 4.3.1 Global Overactive Bladder (OAB) Therapeutics Revenue by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Overactive Bladder (OAB) Therapeutics Revenue by Type (2021-2032)
  11. 4.3.3 Global Overactive Bladder (OAB) Therapeutics Revenue Market Share by Type (2021-2032)
5 Overactive Bladder (OAB) Therapeutics Market by Application
  1. 5.1 Overactive Bladder (OAB) Therapeutics Application Introduction
  2. 5.1.1 Hosptial
  3. 5.1.2 Clinci
  4. 5.1.3 Other
  5. 5.2 Global Overactive Bladder (OAB) Therapeutics Sales by Application
  6. 5.2.1 Global Overactive Bladder (OAB) Therapeutics Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Overactive Bladder (OAB) Therapeutics Sales by Application (2021-2032)
  8. 5.2.3 Global Overactive Bladder (OAB) Therapeutics Sales Market Share by Application (2021-2032)
  9. 5.3 Global Overactive Bladder (OAB) Therapeutics Revenue by Application
  10. 5.3.1 Global Overactive Bladder (OAB) Therapeutics Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Overactive Bladder (OAB) Therapeutics Revenue by Application (2021-2032)
  12. 5.3.3 Global Overactive Bladder (OAB) Therapeutics Revenue Market Share by Application (2021-2032)
6 Global Overactive Bladder (OAB) Therapeutics Sales by Region
  1. 6.1 Global Overactive Bladder (OAB) Therapeutics Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Overactive Bladder (OAB) Therapeutics Sales by Region (2021-2032)
  3. 6.2.1 Global Overactive Bladder (OAB) Therapeutics Sales by Region (2021-2026)
  4. 6.2.2 Global Overactive Bladder (OAB) Therapeutics Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Overactive Bladder (OAB) Therapeutics Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Overactive Bladder (OAB) Therapeutics Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Overactive Bladder (OAB) Therapeutics Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Overactive Bladder (OAB) Therapeutics Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Overactive Bladder (OAB) Therapeutics Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Overactive Bladder (OAB) Therapeutics Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Overactive Bladder (OAB) Therapeutics Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Overactive Bladder (OAB) Therapeutics Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Overactive Bladder (OAB) Therapeutics Revenue by Region
  1. 7.1 Global Overactive Bladder (OAB) Therapeutics Revenue by Region
  2. 7.1.1 Global Overactive Bladder (OAB) Therapeutics Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Overactive Bladder (OAB) Therapeutics Revenue by Region (2021-2026)
  4. 7.1.3 Global Overactive Bladder (OAB) Therapeutics Revenue by Region (2027-2032)
  5. 7.1.4 Global Overactive Bladder (OAB) Therapeutics Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Overactive Bladder (OAB) Therapeutics Revenue (2021-2032)
  8. 7.2.2 North America Overactive Bladder (OAB) Therapeutics Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Overactive Bladder (OAB) Therapeutics Revenue (2021-2032)
  11. 7.3.2 Europe Overactive Bladder (OAB) Therapeutics Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Overactive Bladder (OAB) Therapeutics Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Overactive Bladder (OAB) Therapeutics Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Overactive Bladder (OAB) Therapeutics Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Overactive Bladder (OAB) Therapeutics Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Allergan
  2. 8.1.1 Allergan Company Information
  3. 8.1.2 Allergan Business Overview
  4. 8.1.3 Allergan Overactive Bladder (OAB) Therapeutics Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Allergan Overactive Bladder (OAB) Therapeutics Product Portfolio
  6. 8.1.5 Allergan Recent Developments
  7. 8.2 Astellas Pharma
  8. 8.2.1 Astellas Pharma Company Information
  9. 8.2.2 Astellas Pharma Business Overview
  10. 8.2.3 Astellas Pharma Overactive Bladder (OAB) Therapeutics Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Astellas Pharma Overactive Bladder (OAB) Therapeutics Product Portfolio
  12. 8.2.5 Astellas Pharma Recent Developments
  13. 8.3 Hisamitsu Pharmaceutical
  14. 8.3.1 Hisamitsu Pharmaceutical Company Information
  15. 8.3.2 Hisamitsu Pharmaceutical Business Overview
  16. 8.3.3 Hisamitsu Pharmaceutical Overactive Bladder (OAB) Therapeutics Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Hisamitsu Pharmaceutical Overactive Bladder (OAB) Therapeutics Product Portfolio
  18. 8.3.5 Hisamitsu Pharmaceutical Recent Developments
  19. 8.4 Ion Channel Innovations
  20. 8.4.1 Ion Channel Innovations Company Information
  21. 8.4.2 Ion Channel Innovations Business Overview
  22. 8.4.3 Ion Channel Innovations Overactive Bladder (OAB) Therapeutics Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Ion Channel Innovations Overactive Bladder (OAB) Therapeutics Product Portfolio
  24. 8.4.5 Ion Channel Innovations Recent Developments
  25. 8.5 Kwang Dong Pharmaceutical
  26. 8.5.1 Kwang Dong Pharmaceutical Company Information
  27. 8.5.2 Kwang Dong Pharmaceutical Business Overview
  28. 8.5.3 Kwang Dong Pharmaceutical Overactive Bladder (OAB) Therapeutics Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Kwang Dong Pharmaceutical Overactive Bladder (OAB) Therapeutics Product Portfolio
  30. 8.5.5 Kwang Dong Pharmaceutical Recent Developments
  31. 8.6 ONO Pharmaceutical
  32. 8.6.1 ONO Pharmaceutical Company Information
  33. 8.6.2 ONO Pharmaceutical Business Overview
  34. 8.6.3 ONO Pharmaceutical Overactive Bladder (OAB) Therapeutics Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 ONO Pharmaceutical Overactive Bladder (OAB) Therapeutics Product Portfolio
  36. 8.6.5 ONO Pharmaceutical Recent Developments
  37. 8.7 Tengion
  38. 8.7.1 Tengion Company Information
  39. 8.7.2 Tengion Business Overview
  40. 8.7.3 Tengion Overactive Bladder (OAB) Therapeutics Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Tengion Overactive Bladder (OAB) Therapeutics Product Portfolio
  42. 8.7.5 Tengion Recent Developments
  43. 8.8 GlaxoSmithKline
  44. 8.8.1 GlaxoSmithKline Company Information
  45. 8.8.2 GlaxoSmithKline Business Overview
  46. 8.8.3 GlaxoSmithKline Overactive Bladder (OAB) Therapeutics Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 GlaxoSmithKline Overactive Bladder (OAB) Therapeutics Product Portfolio
  48. 8.8.5 GlaxoSmithKline Recent Developments
  49. 8.9 Ferring
  50. 8.9.1 Ferring Company Information
  51. 8.9.2 Ferring Business Overview
  52. 8.9.3 Ferring Overactive Bladder (OAB) Therapeutics Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Ferring Overactive Bladder (OAB) Therapeutics Product Portfolio
  54. 8.9.5 Ferring Recent Developments
  55. 8.10 Pfizer
  56. 8.10.1 Pfizer Company Information
  57. 8.10.2 Pfizer Business Overview
  58. 8.10.3 Pfizer Overactive Bladder (OAB) Therapeutics Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Pfizer Overactive Bladder (OAB) Therapeutics Product Portfolio
  60. 8.10.5 Pfizer Recent Developments
  61. 8.11 Lanzhou Institute of Biological Products
  62. 8.11.1 Lanzhou Institute of Biological Products Company Information
  63. 8.11.2 Lanzhou Institute of Biological Products Business Overview
  64. 8.11.3 Lanzhou Institute of Biological Products Overactive Bladder (OAB) Therapeutics Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Lanzhou Institute of Biological Products Overactive Bladder (OAB) Therapeutics Product Portfolio
  66. 8.11.5 Lanzhou Institute of Biological Products Recent Developments
  67. 8.12 Merck
  68. 8.12.1 Merck Company Information
  69. 8.12.2 Merck Business Overview
  70. 8.12.3 Merck Overactive Bladder (OAB) Therapeutics Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Merck Overactive Bladder (OAB) Therapeutics Product Portfolio
  72. 8.12.5 Merck Recent Developments
  73. 8.13 Sanofi
  74. 8.13.1 Sanofi Company Information
  75. 8.13.2 Sanofi Business Overview
  76. 8.13.3 Sanofi Overactive Bladder (OAB) Therapeutics Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Sanofi Overactive Bladder (OAB) Therapeutics Product Portfolio
  78. 8.13.5 Sanofi Recent Developments
  79. 8.14 Teva Pharmaceutical Industries
  80. 8.14.1 Teva Pharmaceutical Industries Company Information
  81. 8.14.2 Teva Pharmaceutical Industries Business Overview
  82. 8.14.3 Teva Pharmaceutical Industries Overactive Bladder (OAB) Therapeutics Sales, Price, Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Teva Pharmaceutical Industries Overactive Bladder (OAB) Therapeutics Product Portfolio
  84. 8.14.5 Teva Pharmaceutical Industries Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Overactive Bladder (OAB) Therapeutics Value Chain Analysis
  2. 9.1.1 Overactive Bladder (OAB) Therapeutics Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Overactive Bladder (OAB) Therapeutics Production Mode & Process
  6. 9.2 Overactive Bladder (OAB) Therapeutics Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Overactive Bladder (OAB) Therapeutics Distributors
  9. 9.2.3 Overactive Bladder (OAB) Therapeutics Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst